Introduction: There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited‐stage, patients with SCLC. Methods: We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once‐daily Versus twice‐daily RadioTherapy (CONVERT) trial. Patients were randomized to receive 45 Gy/30 twice‐daily fractions/19 days or 66 Gy/33 once‐daily fractions/45 days concurrently with platinum‐based chemotherapy. Overall survival and progression‐free survival were evaluated using Kaplan‐Meier methodology and Cox proportional hazards regression. Results: Of 547 patients randomized between April 2008 and November 2013, 57 did not receive protocol treatment and were excluded. Of the 490 patients included, 67 (14%) were 70 years of age or older (median age: 73 years; range: 70–82). Fewer older patients received the optimal number of radiotherapy fractions (73% versus 85%; p = 0.03); however, chemotherapy compliance was similar in both groups (p = 0.24). Neutropenia grade 3/4 occurred more frequently in the elderly (84% versus 70%; p = 0.02) but rates of neutropenic sepsis (4% versus 7%; p = 0.07) and death (3% versus 1.4%; p = 0.67) were similar in both groups. With a median follow‐up of 46 months; median survival in the elderly versus younger groups was 29 (95% confidence interval [CI]: 21–39) versus 30 months (95% CI: 26–35), respectively; (hazard ratio: 1.15, 95% CI: 0.84–1.59; p = 0.38). Median time to progression in the elderly versus younger groups was 18 months (95% CI: 13–31) versus 16 months (95% CI: 14–19), respectively (hazard ratio: 1.04, 95% CI: 0.76–1.41; p = 0.81). Conclusions: Concurrent chemoradiotherapy with modern radiotherapy techniques should be a treatment option for fit, older patients.

中文翻译：

---

在并发每日一次与每日两次放射治疗 (CONVERT) 试验中接受治疗的老年患者的依从性和结果

简介：目前缺乏关于同步放化疗对老年、局限期、SCLC 患者的疗效和安全性的数据。方法：我们比较了 70 岁或以上患者与较年轻患者在每日一次与每日两次并发放射治疗 (CONVERT) 试验中的结果。患者随机接受 45 Gy/30 次每日两次/19 天或 66 Gy/33 次每日一次/45 天，同时接受铂类化疗。使用 Kaplan-Meier 方法和 Cox 比例风险回归评估总生存期和无进展生存期。结果：在 2008 年 4 月至 2013 年 11 月期间随机分配的 547 名患者中，57 名未接受方案治疗并被排除在外。在包括的 490 名患者中，67 名 (14%) 的年龄为 70 岁或以上（中位年龄：73 岁；范围：70-82）。接受最佳放射治疗次数的老年患者较少（73% 对 85%；p = 0.03）；然而，两组的化疗依从性相似（p = 0.24）。中性粒细胞减少症 3/4 级在老年人中更常见（84% 对 70%；p = 0.02），但中性粒细胞减少性败血症（4% 对 7%；p = 0.07）和死亡率（3% 对 1.4%；p = 0.67） ) 在两组中相似。中位随访时间为 46 个月；老年人组与年轻组的中位生存期分别为 29（95% 置信区间 [CI]：21-39）和 30 个月（95% CI：26-35）；（风险比：1.15，95% CI：0.84–1.59；p = 0.38）。老年人组与年轻组的中位进展时间分别为 18 个月（95% CI：13-31）和 16 个月（95% CI：14-19）（风险比：1.04，95% CI：0.76-1.41； p = 0.81）。结论：